Uncategorized
TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces new pooled efficacy data for TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).